Rovelizumab (Hu23F2G) is a humanized monoclonal antibody targeting the cell adhesion molecule CD11/CD18. It inhibits overactive leukocytes during shock and may be used in studies of multiple sclerosis (MS), hemorrhagic shock, myocardial infarction, and stroke.
Purity:
95.00%
CAS Number:
[339086-79-2]
Target:
Integrin|||Complement System
* VAT and and shipping costs not included. Errors and price changes excepted
